Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
Kai QinKazuhito HonjoScott Sherrill-MixWeimin LiuRegina M StoltzAllisa K OmanLucinda A HallRan LiSarah SterrettEllen R FrederickJeffrey R LancasterMayur NarkhedeAmitkumar MehtaFoluso J OgunsileRima B PatelThomas J KetasVictor M Cruz PortilloAlbert CupoBenjamin M LarimerPaul A GoepfertPaul A GoepfertBeatrice H HahnRandall S DavisPublished in: PLoS medicine (2023)
CLL pathogenesis is characterized by a progressive loss of adaptive immune functions, including in most treatment-naïve patients, with preexisting memory being preserved longer than the capacity to mount responses to new antigens. In addition, higher NAb titers and response rates identify mRNA-1273 as a superior vaccine for CLL patients.
Keyphrases
- chronic lymphocytic leukemia
- sars cov
- end stage renal disease
- multiple sclerosis
- chronic kidney disease
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- oxidative stress
- working memory
- binding protein
- respiratory syndrome coronavirus
- advanced non small cell lung cancer
- combination therapy
- smoking cessation
- replacement therapy